Skip to main content
. 2022 Apr 27;42(2):487–496. doi: 10.1002/jum.15991

Table 1.

Baseline Characteristics for the Total Population 137 Participants and in the Two Etiology Groups: ALD and NAFLD

Total Population ALD NAFLD P
n = 137 n = 77 n = 60
Age 60 (53–65) 61 (55–54) 58 (53–65) .538
Gender, male (%) 98 (72) 66 (86) 32 (53) .000
BMI (kg/m2) 32 (28–38) 30 (27–35) 35 (31–41) .000
Waistline (cm) 110 (103–123) 109 (102–120) 114 (106–126) .045
Skin to capsule distance (cm) 2.2 (1.9–2.7) 2.2 (1.8–2.5) 2.4 (2.1–2.9) .005
Diabetes, yes 42 (31) 17 (22) 25 (42) .016
Transient elastography 9.7 (7.5–15.8) 9.2 (7.8–14.4) 10.2 (7.7–16.1) .646
Steatosis markers
B‐mode ratio a 1.37 (1.15–1.60) 1.41 (1.15–1.65) 1.29 (1.17–1.56) .165
Controlled attenuation parameter (CAP) (dB/m) a 337 (298–365) 334 (281–368) 346 (314–365) .194
Ultrasonic steatosis score 18/28/39/51 13/20/20/24 5/8/19/27 .089
S0/1/2/3 (%) a (13/20/28/37) (17/26/26/31) (8/13/32/45)
Fatty liver index 92 (92–93) 92 (91–93) 93 (92–93) .034
Histology
Histological steatosis grade 28/50/33/26 19/25/18/15 9/25/15/11 .507
S0/1/2/3 (%) (20/37/24/19) (25/32/23/19) (15/42/25/18)
Kleiner fibrosis score 6/47/43/25/16 4/21/26/15/11 2/26/17/10/5 .383
F0/1/2/3/4 (%) (4/34/31/18/12) (5/27/34/19/14) (3/43/28/17/8)
Presence of steatohepatitis (%) 51 (37) 28 (36) 23 (38) .860
Laboratory tests
ALT (U/L) 41 (29–59) 39 (25–58) 41 (32–60) .203
AST (U/L) 39 (27–57) 42 (26–58) 36 (27–49) .458
Bilirubin (μmol/L) 9 (6–12) 9 (6–11) 9 (6–12) .516
GGT (U/L) 85 (42–196) 102 (52–302) 58 (36–139) .003
MELD (points) 7 (6–8) 7 (6–8) 7 (6–8) .852

Continuous variables are reported as median (IQR) and categorical data as frequencies (%). The P‐value describes the difference between the two etiology groups (ALD versus NAFLD). The between‐group differences were calculated using Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma‐glutamyl transferase.

a

It was not possible to evaluate B‐mode ratio in 16 (12%), ultrasonic steatosis score in 1 (1%), and CAP in 3 (2%).